Nearly one in eight men will be diagnosed with prostate cancer and, as a new UCSF study finds, significantly more of these ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

After a change in screening guidelines, the incidence increased across the state, surpassing the national trend. A new study ...

Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on ...

High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...

The 18-gene MyProstateScore 2.0 (MPS2) test using first-catch non-digital rectal examination (DRE) urine is highly sensitive ...

A new study by UC San Francisco found that prostate cancer cases are increasing in California, likely due to a change in ...

First Focal One® procedure utilizing Cortechs.ai’s advanced MRI-imaging technology, OnQ Prostate, successfully performed at the University of ...

Cortechs.ai and EDAP TMS (EDAP) announced the successful completion of the world’s first OnQ Prostate-assisted Focal One Robotic HIFU procedure ...

For decades, scientists have tried to stop cancer by disabling the mutated proteins that are found in tumors. But many cancers manage to overcome this and continue growing. Now, scientists think they ...